New Cancer Med Is Giving Patients Hope, But One Former Senator Says It Comes With A “Nasty” Catch

Live updates

1. 16d ago

   FDA Approves Pancreatic Cancer Drug Rasonque

   The FDA has approved Rasonque (daraxonrasib), a breakthrough medication designed to treat pancreatic cancer and extend patient lives. Developed by the independent firm RevMed, the drug is described by medical researchers and news outlets as a landmark treatment for an intractable disease. While the approval marks a new era for oncology, the medication carries a monthly list price of $39,800. Early reports indicate the drug has already helped some patients shrink tumors, though concerns remain regarding patient access and affordability.

   Why it matters

   Pancreatic cancer is traditionally difficult to treat, making any FDA-approved breakthrough significant for survival rates. The drug's high cost and the independent status of its maker, RevMed, create a tension between medical innovation and patient accessibility.

   What is confirmed

   • The FDA approved the pancreatic cancer drug Rasonque, also known as daraxonrasib.
   • RevMed is the drugmaker behind the new pancreatic cancer treatment.
   • The medication is intended to extend the lives of patients with pancreatic cancer.

   Still unconfirmed

   • The monthly list price for Rasonque is $39,800.
   • A former senator claims the drug comes with a nasty catch.
   • Trump's cuts threaten access to the medication.

   What to watch next

   • Insurance coverage determinations for Rasonque
   • Clinical data on long-term survival rates
   • RevMed's distribution and launch strategy
   Sources used for this update (18)

   1. WSJ — FDA Approves Drug for Pancreatic Cancer in Incredible Moment for Deadly Disease
   2. The New York Times — F.D.A. Approves Drug Poised to Transform Care for Pancreatic Cancer
   3. STAT — FDA approves new pancreatic cancer drug expected to usher in new era of treatment
   4. Bloomberg — A Breakthrough Pancreatic Cancer Drug Marks a New Era for Treatment
   5. The Washington Post — FDA approves ‘landmark’ pancreatic cancer drug that extends patients’ lives
   6. Scientific American — U.S. approves breakthrough pancreatic cancer drug, heralding a new era for an intractable disease
   7. BBC — FDA approves breakthrough drug daraxonrasib to treat pancreatic cancer
   8. Pancreatic Cancer Action Network — FDA Approves RASONQUE™ (daraxonrasib)
   9. The New York Times — The Race to Develop More Medicines Like the New Pancreatic Cancer Drug
   10. Fierce Pharma — As RevMed preps for ‘historic’ pancreatic cancer launch, questions linger on the ground
   11. BioSpace — RevMed could become ‘next oncology titan’ with Rasonque nod
   12. WSJ — Why the Drugmaker Behind a Pancreatic Cancer Breakthrough Stayed Independent
   confidence 90%